Prothena (PRTA) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

PRTA Stock Forecast

Prothena stock forecast is as follows: an average price target of $58.50 (represents a 316.37% upside from PRTA’s last price of $14.05) and a rating consensus of 'Buy', based on 16 wall street analysts offering a 1-year stock forecast.

PRTA Price Target

The average price target for Prothena (PRTA) is $58.50 based on 1-year price targets from 16 Wall Street analysts in the past 3 months, with a price target range of $98.00 to $24.00. This represents a potential 316.37% upside from PRTA's last price of $14.05.

PRTA Analyst Ratings

Buy

According to 16 Wall Street analysts, Prothena's rating consensus is 'Buy'. The analyst rating breakdown for PRTA stock is 0 'Strong Buy' (0.00%), 12 'Buy' (75.00%), 4 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Prothena Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Aug 14, 2024	Jay Olson	Oppenheimer	$62.00	$19.77	213.61%	341.28%
Aug 09, 2024	Kennen MacKay	RBC Capital	$24.00	$19.68	21.95%	70.82%
May 09, 2024	Kennen MacKay	RBC Capital	$28.00	$23.03	21.58%	99.29%
Dec 21, 2022	-	Cantor Fitzgerald	$98.00	$58.98	66.17%	597.51%
Sep 29, 2022	-	Oppenheimer	$110.00	$59.47	84.97%	682.92%
Sep 28, 2022	-	RBC Capital	$52.00	$55.39	-6.13%	270.11%
May 25, 2022	-	JMP Securities	$50.00	$25.95	92.68%	255.87%

Row per page

Go to

The latest Prothena stock forecast, released on Aug 14, 2024 by Jay Olson from Oppenheimer, set a price target of $62.00, which represents a 213.61% increase from the stock price at the time of the forecast ($19.77), and a 341.28% increase from PRTA last price ($14.05).

Prothena Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	3
Avg Price Target	-	-	$38.00
Last Closing Price	$14.05	$14.05	$14.05
Upside/Downside	-100.00%	-100.00%	170.46%

In the current month, the average price target of Prothena stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Prothena's last price of $14.05. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 29, 2024	Oppenheimer	Outperform	Outperform	Hold
Oct 01, 2024	RBC Capital	Sector Perform	Sector Perform	Hold
Oct 01, 2024	H.C. Wainwright	Buy	Buy	Hold
Sep 30, 2024	Oppenheimer	Outperform	Outperform	Hold
Aug 14, 2024	Oppenheimer	Outperform	Outperform	Hold
Aug 09, 2024	RBC Capital	Sector Perform	Sector Perform	Hold
May 29, 2024	Piper Sandler	Overweight	Overweight	Hold
May 09, 2024	RBC Capital	Sector Perform	Sector Perform	Hold
Mar 13, 2024	RBC Capital	Sector Perform	Sector Perform	Hold
Feb 16, 2024	RBC Capital	Sector Perform	Sector Perform	Hold

Row per page

Go to

Prothena's last stock rating was published by Oppenheimer on Oct 29, 2024. The company gave PRTA a "Outperform" rating, the same as its previous rate.

Prothena Financial Forecast

Prothena Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$84.87M	$4.02M	$2.17M	$49.92M	$1.52M	$1.31M	$1.15M	$1.17M	$139.17M	$60.07M	$160.00K	$360.00K	$157.00K	$195.00K	$141.00K	$256.00K	$205.00K
Avg Forecast	$51.55M	$22.00M	$18.00M	$10.00M	$38.13M	$1.22M	$1.15M	$5.05M	$8.35M	$1.35M	$10.73M	$2.17M	$2.15M	$41.69M	$5.09M	$8.60M	$29.14M	$25.22M	$17.18M	$8.09M	$7.12M	$140.05M	$70.20M	$8.68M	$182.76K	$160.83K	$150.00K	$171.43K	$175.00K	$175.00K
High Forecast	$148.35M	$63.31M	$51.80M	$28.78M	$109.73M	$3.50M	$3.31M	$14.53M	$29.66M	$1.36M	$10.73M	$2.17M	$3.99M	$41.69M	$14.65M	$24.75M	$83.85M	$25.22M	$17.18M	$8.09M	$7.12M	$140.05M	$70.20M	$8.68M	$182.76K	$160.83K	$150.00K	$171.43K	$175.00K	$175.00K
Low Forecast	$14.23M	$6.07M	$4.97M	$2.76M	$10.52M	$335.44K	$317.05K	$1.39M	$136.45K	$1.33M	$10.73M	$2.17M	$458.54K	$41.69M	$1.41M	$2.37M	$8.04M	$25.22M	$17.18M	$8.09M	$7.12M	$140.05M	$70.20M	$8.68M	$182.76K	$160.83K	$150.00K	$171.43K	$175.00K	$175.00K
# Analysts	1	1	1	1	1	1	1	1	6	3	1	1	3	9	6	4	3	7	4	3	4	7	4	4	4	9	9	9	8	8
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	2.04%	0.79%	0.25%	1.71%	0.06%	0.08%	0.14%	0.16%	0.99%	0.86%	0.02%	1.97%	0.98%	1.30%	0.82%	1.46%	1.17%

Prothena's average Quarter revenue forecast for Dec 23 based on 3 analysts is $2.15M, with a low forecast of $458.54K, and a high forecast of $3.99M. PRTA's average Quarter revenue forecast represents a -97.46% decrease compared to the company's last Quarter revenue of $84.87M (Sep 23).

Prothena EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	1	6	3	1	1	3	9	6	4	3	7	4	3	4	7	4	4	4	9	9	9	8	8
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$10.31M	$-66.50M	$-56.33M	$-72.00K	$-50.33M	$-41.55M	$-36.30M	$-31.40M	$110.92M	$29.61M	$-30.36M	$-28.61M	$-28.99M	$-24.62M	$-20.87M	$-18.38M	$-17.27M
Avg Forecast	$-37.54M	$-16.02M	$-13.11M	$-7.28M	$-27.77M	$-885.04K	$-836.53K	$-3.68M	$-6.08M	$-980.75K	$-7.81M	$-27.08M	$-1.57M	$-30.36M	$-3.71M	$-28.97M	$-30.55M	$-18.36M	$-12.51M	$-30.98M	$-5.18M	$-101.99M	$-51.12M	$-21.76M	$-133.09K	$-117.12K	$-109.23K	$-20.14M	$-127.44K	$-127.44K
High Forecast	$-10.36M	$-4.42M	$-3.62M	$-2.01M	$-7.66M	$-244.28K	$-230.89K	$-1.02M	$-99.37K	$-967.73K	$-7.81M	$-21.67M	$-333.92K	$-30.36M	$-1.02M	$-23.17M	$-24.44M	$-18.36M	$-12.51M	$-24.78M	$-5.18M	$-101.99M	$-51.12M	$-17.40M	$-133.09K	$-117.12K	$-109.23K	$-16.11M	$-127.44K	$-127.44K
Low Forecast	$-108.03M	$-46.10M	$-37.72M	$-20.96M	$-79.91M	$-2.55M	$-2.41M	$-10.58M	$-21.60M	$-993.76K	$-7.81M	$-32.50M	$-2.90M	$-30.36M	$-10.67M	$-34.76M	$-36.66M	$-18.36M	$-12.51M	$-37.17M	$-5.18M	$-101.99M	$-51.12M	$-26.11M	$-133.09K	$-117.12K	$-109.23K	$-24.16M	$-127.44K	$-127.44K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.34%	17.94%	1.94%	0.00%	2.74%	3.32%	1.17%	6.06%	-1.09%	-0.58%	1.40%	214.92%	247.51%	225.37%	1.04%	144.25%	135.50%

3 analysts predict PRTA's average Quarter EBITDA for Dec 23 to be $-1.57M, with a high of $-333.92K and a low of $-2.90M. This is -115.21% lower than Prothena's previous annual EBITDA (Sep 23) of $10.31M.

Prothena Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	1	6	3	1	1	3	9	6	4	3	7	4	3	4	7	4	4	4	9	9	9	8	8
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$21.91M	$-54.59M	$-46.86M	$6.35M	$-45.76M	$-41.24M	$-36.29M	$-33.18M	$109.25M	$27.64M	$-36.73M	$-30.72M	$-30.58M	$-26.28M	$-23.57M	$-21.55M	$-19.45M
Avg Forecast	$-45.72M	$-69.39M	$-69.93M	$-75.31M	$-75.31M	$-72.35M	$-69.66M	$-68.85M	$-53.99M	$-62.80M	$-56.96M	$-27.06M	$-63.23M	$-17.36M	$-50.17M	$-28.94M	$-32.28M	$-32.21M	$-28.80M	$-30.95M	$-32.13M	$124.60M	$54.94M	$-26.32M	$-42.30M	$-35.87M	$-33.85M	$-22.74M	$-32.84M	$-28.16M
High Forecast	$-2.69M	$-4.08M	$-4.11M	$-4.43M	$-4.43M	$-4.25M	$-4.10M	$-63.16M	$-31.01M	$-3.69M	$-3.35M	$-21.65M	$-44.73M	$1.63M	$-2.95M	$-23.15M	$-25.82M	$-32.21M	$-28.80M	$-24.76M	$-32.13M	$124.60M	$55.30M	$-21.06M	$-42.30M	$-35.87M	$-33.85M	$-18.19M	$-32.84M	$-28.16M
Low Forecast	$-157.33M	$-238.77M	$-240.62M	$-259.13M	$-259.13M	$-248.95M	$-239.69M	$-74.03M	$-65.22M	$-216.09M	$-195.99M	$-32.47M	$-75.06M	$-75.42M	$-172.65M	$-34.73M	$-38.74M	$-32.21M	$-28.80M	$-37.14M	$-32.13M	$124.60M	$54.58M	$-31.59M	$-42.30M	$-35.87M	$-33.85M	$-27.29M	$-32.84M	$-28.16M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-1.26%	1.09%	1.62%	-0.20%	1.42%	1.43%	1.17%	1.03%	0.88%	0.50%	1.40%	0.73%	0.85%	0.78%	1.04%	0.66%	0.69%

Prothena's average Quarter net income forecast for Dec 23 is $-63.23M, with a range of $-75.06M to $-44.73M. PRTA's average Quarter net income forecast represents a -388.64% decrease compared to the company's last Quarter net income of $21.91M (Sep 23).

Prothena SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	1	6	3	1	1	3	9	6	4	3	7	4	3	4	7	4	4	4	9	9	9	8	8
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$16.64M	$14.51M	$13.74M	$13.12M	$11.99M	$12.95M	$11.84M	$12.21M	$11.96M	$11.03M	$11.13M	$9.91M	$9.40M	$9.66M	$9.74M	$8.06M	$8.69M
Avg Forecast	$939.36M	$400.87M	$327.99M	$182.22M	$694.79M	$22.15M	$20.93M	$92.02M	$152.21M	$24.54M	$195.48M	$39.46M	$39.23M	$759.69M	$92.76M	$156.71M	$11.88M	$459.51M	$312.96M	$147.32M	$129.69M	$2.55B	$1.28B	$7.97M	$3.33M	$2.93M	$2.73M	$3.12M	$3.19M	$3.19M
High Forecast	$2.70B	$1.15B	$943.85M	$524.36M	$2.00B	$63.73M	$60.23M	$264.80M	$540.51M	$24.87M	$195.48M	$39.46M	$72.65M	$759.71M	$266.93M	$450.95M	$14.25M	$459.51M	$312.96M	$147.32M	$129.69M	$2.55B	$1.28B	$9.57M	$3.33M	$2.93M	$2.73M	$3.12M	$3.19M	$3.19M
Low Forecast	$259.27M	$110.64M	$90.53M	$50.29M	$191.77M	$6.11M	$5.78M	$25.40M	$2.49M	$24.21M	$195.47M	$39.45M	$8.36M	$759.67M	$25.60M	$43.25M	$9.50M	$459.51M	$312.96M	$147.32M	$129.69M	$2.55B	$1.28B	$6.38M	$3.33M	$2.93M	$2.73M	$3.12M	$3.19M	$3.19M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.02%	0.16%	0.09%	1.11%	0.03%	0.04%	0.08%	0.09%	0.00%	0.01%	1.40%	2.98%	3.21%	3.53%	3.12%	2.53%	2.73%

Prothena's average Quarter SG&A projection for Dec 23 is $39.23M, based on 3 Wall Street analysts, with a range of $8.36M to $72.65M. The forecast indicates a 135.71% rise compared to PRTA last annual SG&A of $16.64M (Sep 23).

Prothena EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	1	6	3	1	1	3	9	6	4	3	7	4	3	4	7	4	4	4	9	9	9	8	8
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$0.41	$-1.03	$-0.89	$0.13	$-0.97	$-0.88	$-0.78	$-0.71	$2.39	$0.62	$-0.91	$-0.77	$-0.77	$-0.66	$-0.59	$-0.54	$-0.49
Avg Forecast	$-0.85	$-1.29	$-1.30	$-1.40	$-1.40	$-1.34	$-1.29	$-1.28	$-1.00	$-1.17	$-1.06	$-1.16	$-1.18	$-0.32	$-0.93	$-0.87	$-0.47	$-0.59	$-0.52	$-0.69	$-0.58	$2.26	$1.00	$-0.57	$-0.77	$-0.65	$-0.61	$-0.57	$-0.60	$-0.51
High Forecast	$-0.05	$-0.08	$-0.08	$-0.08	$-0.08	$-0.08	$-0.08	$-1.17	$-0.58	$-0.07	$-0.06	$-0.07	$-0.83	$0.03	$-0.05	$-0.05	$-0.03	$-0.59	$-0.52	$-0.69	$-0.58	$2.26	$1.00	$-0.57	$-0.77	$-0.65	$-0.61	$-0.57	$-0.60	$-0.51
Low Forecast	$-2.92	$-4.44	$-4.47	$-4.82	$-4.82	$-4.63	$-4.46	$-1.38	$-1.21	$-4.02	$-3.64	$-3.98	$-1.40	$-1.40	$-3.21	$-3.00	$-1.60	$-0.59	$-0.52	$-0.69	$-0.58	$2.26	$0.99	$-0.57	$-0.77	$-0.65	$-0.61	$-0.57	$-0.60	$-0.51
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-1.27%	1.10%	1.02%	-0.28%	1.66%	1.68%	1.13%	1.22%	1.06%	0.62%	1.60%	1.00%	1.18%	1.07%	1.03%	0.91%	0.96%

According to 3 Wall Street analysts, Prothena's projected average Quarter EPS for Dec 23 is $-1.18, with a low estimate of $-1.40 and a high estimate of $-0.83. This represents a -386.72% decrease compared to PRTA previous annual EPS of $0.41 (Sep 23).

Prothena Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
VTYX	Ventyx Biosciences	$1.78	$33.86	1802.25%	Buy
LIFE	aTyr Pharma	$1.90	$11.00	478.95%	Buy
MIST	Milestone Pharmaceuticals	$1.74	$10.00	474.71%	Buy
PRTA	Prothena	$14.05	$58.50	316.37%	Buy
PLRX	Pliant Therapeutics	$12.79	$39.71	210.48%	Buy
ETNB	89bio	$7.99	$22.00	175.34%	Buy
STOK	Stoke Therapeutics	$11.61	$30.60	163.57%	Buy
CGEM	Cullinan Oncology	$13.10	$31.50	140.46%	Buy
IMCR	Immunocore	$32.56	$70.75	117.29%	Buy
VRDN	Viridian Therapeutics	$20.24	$37.92	87.35%	Buy
MCRB	Seres Therapeutics	$0.69	$1.25	81.16%	Buy
KNSA	Kiniksa Pharmaceuticals	$20.82	$36.33	74.50%	Buy
PCVX	Vaxcyte	$87.08	$124.00	42.40%	Buy
DICE	DICE Therapeutics	$47.55	$60.00	26.18%	Buy
NUVL	Nuvalent	$91.06	$111.57	22.52%	Buy
MDGL	Madrigal Pharmaceuticals	$314.17	$315.75	0.50%	Buy
ACLX	Arcellx	$87.59	$83.00	-5.24%	Buy

PRTA Forecast FAQ

Is Prothena a good buy?

Yes, according to 16 Wall Street analysts, Prothena (PRTA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 12 'Buy' recommendations, accounting for 75.00% of PRTA's total ratings.

What is PRTA's price target?

Prothena (PRTA) average price target is $58.5 with a range of $24 to $98, implying a 316.37% from its last price of $14.05. The data is based on 16 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Prothena stock go up soon?

According to Wall Street analysts' prediction for PRTA stock, the company can go up by 316.37% (from the last price of $14.05 to the average price target of $58.5), up by 597.51% based on the highest stock price target, and up by 70.82% based on the lowest stock price target.

Can Prothena stock reach $20?

PRTA's average twelve months analyst stock price target of $58.5 supports the claim that Prothena can reach $20 in the near future.

What are Prothena's analysts' financial forecasts?

Prothena's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $45.54M (high $131.06M, low $12.57M), average EBITDA is $-33.167M (high $-9.154M, low $-95.443M), average net income is $-286M (high $-75.937M, low $-822M), average SG&A $829.88M (high $2.39B, low $229.05M), and average EPS is $-5.32 (high $-1.412, low $-15.278). PRTA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $101.55M (high $292.23M, low $28.03M), average EBITDA is $-73.953M (high $-20.412M, low $-213M), average net income is $-260M (high $-15.31M, low $-896M), average SG&A $1.85B (high $5.32B, low $510.73M), and average EPS is $-4.84 (high $-0.285, low $-16.654).

Did the PRTA's actual financial results beat the analysts' financial forecasts?

Based on Prothena's last annual report (Dec 2022), the company's revenue was $53.9M, which missed the average analysts forecast of $79.62M by -32.29%. Apple's EBITDA was $-132M, beating the average prediction of $-92.4M by 42.38%. The company's net income was $-117M, missing the average estimation of $-124M by -5.87%. Apple's SG&A was $49.9M, missing the average forecast of $931.66M by -94.64%. Lastly, the company's EPS was $-2.47, beating the average prediction of $-2.266 by 9.03%. In terms of the last quarterly report (Sep 2023), Prothena's revenue was $84.87M, beating the average analysts' forecast of $41.69M by 103.56%. The company's EBITDA was $10.31M, missing the average prediction of $-30.361M by -133.95%. Prothena's net income was $21.91M, missing the average estimation of $-17.362M by -226.18%. The company's SG&A was $16.64M, missing the average forecast of $759.69M by -97.81%. Lastly, the company's EPS was $0.41, missing the average prediction of $-0.323 by -227.03%